TP53 and neoplasm: AURKA activates HDM2, leading to the ubiquitination of p53; its inhibition markedly decreases cell survival in vitro, and in vivo in a xenograft tumor growth model, suggesting that AURKA expression can indicate a poor response to chemotherapy in GCs 35.